Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026

Mobile Blood Gas Analyzer for Hospital POC Launched

By LabMedica International staff writers
Posted on 19 Jul 2012
AACC 2012: A mobile blood gas analyzer, together with a diverse portfolio of new diagnostics testing solutions is launched. More...


Roche Diagnostics (Basel, Switzerland) is showcasing its new technology at the annual American Association of Clinical Chemistry (AACC) meeting Expo in Los Angeles (CA, USA), which is taking place July 15-19, 2012.

The cobas b 123 POC system is a mobile blood gas analyzer that offers next-generation technology that helps ensure reliable performance by virtually eliminating the introduction of blood clots that can contribute to analyzer downtime and negatively impact patient care. The cobas b 123 POC system is designed for hospital point-of-care settings.

The analyzer features a four-level clot protection system that helps prevent clots that can lead to reagent pack failures—a major issue for healthcare facilities because replacing the pack takes time away from patient care and wastes usable reagent. The cobas b 123 POC system also offers automatic linearity testing and calibration to simplify both workflow and regulatory compliance.

The cobas p 312 preanalytical system offers sample management on a small footprint. This front-end automation solution offers comprehensive, vendor-neutral sample management for labs with limited floor space. The compact, standalone system performs sample registration, sorting, decapping, and archiving of all sample tubes—including chemistry, immunoassay, hematology, coagulation, and urinalysis—for the entire laboratory, including non-Roche equipment.

It has a throughput of up to 450 tubes per hour, the system is ideal for customers who are looking for an entry-level step into automation for preanalytical workflow.

The cobas CT/NG Test screens for Chlamydia and gonorrhea infection. A polymerase chain reaction (PCR)-based multiplex dual probe assay, this molecular test is used to screen and diagnose Chlamydia and gonorrhea infection in symptomatic and asymptomatic patients. It runs on the automated cobas 4800 system and offers excellent sensitivity and high specificity. The test uses male urine and self-collected vaginal swabs, which are the preferred specimen types according to the CDC. They show high sensitivity yet are less invasive and less painful to collect than urethral or endocervical samples and thus may help promote screening compliance.

Roche is a biotech company with differentiated medicines in oncology, virology, inflammation, metabolism, and CNS. The company is also a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.